Treatment of non cognitive symptoms of Alzheimer's disease;Tratamiento de los síntomas no cognitivos de la enfermedad de Alzheimer

Revista de Neurologia

Volumn 42, Issue 8, 2006, Pages 482-488

  Grau Veciana, José M ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Alzheimer's disease; Antidepressive treatments; Antipsychotic treatments

Indexed keywords

FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DELUSION; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFECT; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HEART RATE; HUMAN; HYPOTENSION; MONOTHERAPY; MORTALITY; MOTOR DYSFUNCTION; MULTIPLE CYCLE TREATMENT; PSYCHOSIS; QT INTERVAL; REVIEW; SEDATION; SIDE EFFECT; TACHYCARDIA; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COGNITION DISORDERS; DEPRESSION; FLUOXETINE; HUMANS; PAROXETINE; PSYCHOTIC DISORDERS; RISPERIDONE; SEROTONIN UPTAKE INHIBITORS;

EID: 33750116129     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4208.2005217     Document Type: Review

References (30)

1. Yeager BF, Farnett LE, Ruzicka SA. Management of the behavioral manifestations of dementia. Arch Intern Med 1995; 155: 250-60.
2. Borson S, Raskind MA. Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease. Neurology 1997; 48 (Suppl 6): S17-24.
3. Lantz MS, Marin D. Pharmacological treatment of agitation in dementia: a comprehensive review. J Geriatr Psychiatry Neurol 1996; 9: 107-19.
4. Haley WE. The family caregiver's role in Alzheimer's disease. Neurology 1997; 48 (Suppl 6): S25-9.
5. Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer's disease. Amer J Psychiatry 1989; 146: 577-87.
6. Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38: 553-63.
7. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities. Arch Gen Psychiatry 2000; 57: 968-76.
8. Clark WS, Street JS, Feldman PD, Breier A. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. J Clin Psychiatry 2001; 62: 30-4.
9. Street JS, Clark WS, Kadam DL, Mitan SJ, Juliar BE, Feldman PD, et al. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. Int J Geriatr Psychiatry 2001; 16: 562-70.
10. Mintzer J, Faison W, Street JS, Sutton WK, Breier A. Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis. Int J Geriatr Psychiatry 2001; 16 (Suppl 1): S71-7.
11. Kinon B, Targum S, Basson B, Johnson SE, Stauffer VL. Olanzapine in the management of behavioral disturbances and/or psychosis in demented nursing home patients. J Amer Geriatr Soc 2000; 48: 48.
12. Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002; 26: 494-504.
13. Edell WS, Tunis SL. Antipsychotic treatment og behavioral and psychological symptoms of dementia in geropsychiatric inpatients. J Geriatr Psychiatry 2001; 9: 289-97.
14. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60: 107-15.
15. Brodaly H, Ames D, Snowdon J, Woodward M, Kirwan J, Clasnette R, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64: 134-43.
16. Kennedy JS, Bymaster FP, Schuh L, Calligaro DO, Nomikos G, Felder CC, et al. A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data. Int J Geriatr Psychiatry 2001; 16 (Suppl 1): S33-61.
17. Kennedy JS, Zagar A, Bymaster FP, Nomikos G, Trzepackz PT, Gilmare JA, et al. The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease. Int J Geriatric Psychiatry 2001; 16 (Suppl 1): S24-32.
18. Ellingrod VL, Schultz SK, Ekstam-Schmidt K, Kutscher E, Turvey C, Arndt E. Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis. Pharmacotherapy 2002; 22: 1-5.
19. Cummings JL, Street J, Materman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in with Lewy bodies. Dement Geriatr Cogn Disord 2002; 13: 67-73.
20. Agencia Española de Medicamentos y Productos Sanitarios. Nuevos datos de seguridad sobre los antipsicóticos olanzapina y risperidona en el tratamiento de pacientes ancianos con psicosis o trastornos de conducta asociados a demencia. Nota Informativa. Ref 2004/03. Fecha: 09.03.2004.
21. Alberca R. Tratamiento farmacológico de las manifestaciones psicóticas de la enfermedad de Alzheimer. In Alberca R, ed. Tratamiento de las alteraciones conductuales en la enfermedad de Alzheimer. Madrid: Médica Panamericana; 2002. p. 141-52.
22. Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alheimer's disease. Am J Geriatr Psychiatry 1998: 6; S64-78.
23. Lawlor BA. Possible neurobiological basis for behavioral symptoms. In Lawlor BA, ed. Behavioral complications in Alzheimer disease. Washington DC: American Psychiatric Association; 1995. p. 91-101.
24. Whitehouse PJ, Price DJ, Struble RG, Clark AW, Coyle JT, DeLong MR. Alzheimer disease and senil dementia: loss of neurons in the basal forebrain. Science l982; 215: 1237-9.
25. DeKosky ST. Treatment of cognitive and behavioral impairments in dementia. Pharmacology of Cognition. Toronto: 51st AAN Annual Meeting; 1999.
26. Dorman T. Sleep and paroxetine: a comparison with mianserine in elderly depressed patients. Int Clin Psychopharmacol 1992: 14; 53-8.
27. Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr 2001; 13: 233-40.
28. Taragano FE, Lyketsos CG, Mangone CA, Allegri RF, Comesana-Díaz E. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 1997: 38: 246-52.
29. Mulsant BH, Pollock, BG, Nebes R, Miller MD. Sweet RA, Stack J, et al. A twelve-week, double-blind, randomized comparison of nortriptiline and paroxetine in older depressed inpatients and outpatients. Am J Geriatr Psychiatry 2001; 9: 406-14.
30. Bains J, Birks JS, Denning TR. Antidepressants for treating depression in dementia. Cochrane Library, Issue 1. Chichester, UK: John Wiley; 2004.